|Parameter||Smokers Geometric LS Means||Nonsmokers Geometric LS Means||Ratio of Geometric LS Means (%)||90% CI for Ratio (%)|
|Prasugrel active metabolite|
|AUC0–last (h · ng/ml)||53.6||48.4||110.7||93.7–130.8|
|Clopidogrel active metabolite|
|AUC0–last (h · ng/ml)||19.2||16.2||118.4||99.8–140.4|
|Clopidogrel inactive metabolite|
|AUC0–last (h · ng/ml)||5,025.5||5,816.6||86.4||72.8–102.5|
A mixed-effects model for the crossover design was performed on log-transformed pharmacokinetic (PK) parameters. The model included fixed effects for smoking status, treatment sequence, treatment, treatment period, and smoking status × treatment and a random effect for subject (smoking status × treatment sequence). Geometric LS means are the LS means obtained from the mixed-effects model presented after back-transformation to the original scale. The 90% CIs are presented after back-transformation to the original scale. All mean prasugrel and clopidogrel Cmax and AUC0–last values had 90% CIs that fell outside of the 80% to 125% interval.
AUC0–last = area under the curve up to the last sampling time; Cmax = maximum plasma concentration; other abbreviations as in Tables 2 and 3.